Publication: Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD)
Issued Date
2010-01-01
Resource Type
ISSN
14681293
14642662
14642662
Other identifier(s)
2-s2.0-72449184068
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
HIV Medicine. Vol.11, No.1 (2010), 31-39
Suggested Citation
J. Zhou, P. C.K. Li, N. Kumarasamy, M. Boyd, Y. M.A. Chen, T. Sirisanthana, S. Sungkanuparph, S. Oka, G. Tau, P. Phanuphak, V. Saphonn, F. J. Zhang, S. F.S. Omar, C. K.C. Lee, R. Ditangco, T. P. Merati, P. L. Lim, J. Y. Choi, M. G. Law, S. Pujari Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine. Vol.11, No.1 (2010), 31-39. doi:10.1111/j.1468-1293.2009.00738.x Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/29892
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD)
Other Contributor(s)
Kirby Institute
Queen Elizabeth Hospital Hong Kong
YR Gaitonde Centre for AIDS Research and Education
National Yang-Ming University Taiwan
Research Institute for Health Sciences
Mahidol University
National Center for Global Health and Medicine
Port Moresby General Hospital
The HIV Netherlands Australia Thailand Research Collaboration
National Center for HIV/AIDS
Beijing Ditan Hospital
University of Malaya Medical Centre
Hospital Sungai Buloh
Gokila
Universitas Udayana
Tan Tock Seng Hospital
Yonsei University College of Medicine
Institute of Infectious Diseases
Queen Elizabeth Hospital Hong Kong
YR Gaitonde Centre for AIDS Research and Education
National Yang-Ming University Taiwan
Research Institute for Health Sciences
Mahidol University
National Center for Global Health and Medicine
Port Moresby General Hospital
The HIV Netherlands Australia Thailand Research Collaboration
National Center for HIV/AIDS
Beijing Ditan Hospital
University of Malaya Medical Centre
Hospital Sungai Buloh
Gokila
Universitas Udayana
Tan Tock Seng Hospital
Yonsei University College of Medicine
Institute of Infectious Diseases
Abstract
Objective: The aim of the study was to examine the rates and predictors of treatment modification following combination antiretroviral therapy (cART) failure in Asian patients with HIV enrolled in the TREAT Asia HIV Observational Database (TAHOD). Methods: Treatment failure (immunological, virological and clinical) was defined by World Health Organization criteria. Countries were categorized as high or low income by World Bank criteria. Results: Among 2446 patients who initiated cART, 447 were documented to have developed treatment failure over 5697 person-years (7.8 per 100 person-years). A total of 253 patients changed at least one drug after failure (51.6 per 100 person-years). There was no difference between patients from high- and low-income countries [adjusted hazard ratio (HR) 1.02; . P=0.891]. Advanced disease stage [Centers for Disease Control and Prevention (CDC) category C . vs. A; adjusted HR 1.38, . P=0.040], a lower CD4 count (≥51 cells/μL . vs. ≤50 cells/μL; adjusted HR 0.61, . P=0.022) and a higher HIV viral load (≥400 HIV-1 RNA copies/mL . vs. <400 copies/mL; adjusted HR 2.69, . P<0.001) were associated with a higher rate of treatment modification after failure. Compared with patients from low-income countries, patients from high-income countries were more likely to change two or more drugs (67% . vs. 49%; . P=0.009) and to change to a protease-inhibitor-containing regimen (48% . vs. 16%; . P<0.001). Conclusions: In a cohort of Asian patients with HIV infection, nearly half remained on the failing regimen in the first year following documented treatment failure. This deferred modification is likely to have negative implications for accumulation of drug resistance and response to second-line treatment. There is a need to scale up the availability of second-line regimens and virological monitoring in this region. © 2009 British HIV Association.